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Abstract
The two fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine (4F-Cy-BAP) and furanoyl-1-benzyl-
4-anilinopiperidine (Fu-BAP) have recently been seized as new psychoactive substances (NPS) on the drugs of abuse 
market. As their toxicokinetic and toxicodynamic characteristics are completely unknown, this study focused on elucidat-
ing their in vitro metabolic stability in pooled human liver S9 fraction (pHLS9), their qualitative in vitro (pHLS9), and 
in vivo (zebrafish larvae) metabolism, and their in vitro isozyme mapping using recombinant expressed isoenzymes. Their 
maximum-tolerated concentration (MTC) in zebrafish larvae was studied from 0.01 to 100 µM. Their µ-opioid receptor 
(MOR) activity was analyzed in engineered human embryonic kidney (HEK) 293 T cells. In total, seven phase I and one 
phase II metabolites of 4F-Cy-BAP and 15 phase I and four phase II metabolites of Fu-BAP were tentatively identified by 
means of liquid chromatography high-resolution tandem mass spectrometry, with the majority detected in zebrafish larvae. 
N-Dealkylation, N-deacylation, hydroxylation, and N-oxidation were the most abundant metabolic reactions and the corre-
sponding metabolites are expected to be promising analytical targets for toxicological analysis. Isozyme mapping revealed 
the main involvement of CYP3A4 in the phase I metabolism of 4F-Cy-BAP and in terms of Fu-BAP additionally CYP2D6. 
Therefore, drug-drug interactions by CYP3A4 inhibition may cause elevated drug levels and unwanted adverse effects. 
MTC experiments revealed malformations and changes in the behavior of larvae after exposure to 100 µM Fu-BAP. Both 
substances were only able to produce a weak activation of MOR and although toxic effects based on MOR activation seem 
unlikely, activity at other receptors cannot be excluded.
Keywords In vitro and in vivo metabolism · Metabolic stability · LC–HRMS/MS · Zebrafish larvae · In vitro µ-opioid 
receptor activity
Introduction
More and more compounds intended to be consumed as sub-
stitutes and/or alternatives to classic opioids such as heroin 
are brought into the drugs of abuse market (Beardsley and 
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Zhang 2018). They are summarized under the term new 
synthetic opioids (NSO) and have markedly contributed to 
the dramatic rise in overdose deaths amongst opioid abusers 
(Fagiola et al. 2018; Guerrieri et al. 2017; Muller et al. 2019; 
Sharma et al. 2019; Solimini et al. 2018). This is partly due 
to their nM affinity at the µ-opioid receptor (MOR) and their 
enhanced brain penetration owing to higher lipophilicity, 
but the influence of other toxicodynamic effects cannot be 
excluded as they were often not characterized prior to abuse 
(Baumann et al. 2018). Limited data are also available con-
cerning their toxicokinetics, which is important amongst 
other factors in forensic and clinical toxicology and doping 
control for developing analytical procedures to detect these 
compounds in human biosamples (Wagmann and Maurer 
2018). Furthermore, the knowledge about the toxicokinetics 
and toxicodynamics of emerging NSO and other drugs of 
abuse is essential for law enforcement personnel and poli-
cymakers to allow thorough risk assessment (Evans-Brown 
and Sedefov 2018).
The two fentanyl homologs cyclopropanoyl-1-benzyl-
4′-fluoro-4-anilinopiperidine (4F-Cy-BAP) and furanoyl-
1-benzyl-4-anilinopiperidine (Fu-BAP) have been seized 
in Europe and were intended to be brought onto the mar-
ket as NSO (EMCDDA 2018). Their chemical structures, 
in comparison to fentanyl, are given in Fig. 1. Fu-BAP 
is structurally related to furanylfentanyl, which was risk 
assessed by the EMCDDA in 2017 (EMCDDA 2017). 
Furanylfentanyl differs from Fu-BAP by replacement of 
the phenylethylamine part with phenylmethylamine. So 
far, nothing is known about the toxicokinetic and toxico-
dynamic characteristics of 4F-Cy-BAP and Fu-BAP. How-
ever, N-(1-benzylpiperidin-4-yl)-arylacetamides, structurally 
related compounds, were described to be potent agonists at 
the sigma receptor (Huang et al. 2001), with an affinity of 
N-(1-benzylpiperidin-4-yl)-arylacetamide at the sigma1 and 
sigma2 receptor of 3.9 and 240 nM, respectively. Fu-BAP 
and related compounds were also identified as antagonists at 
the acetylcholine M2 and M3 receptor with Ki values of 794 
and 100 nM for Fu-BAP, respectively (Diouf et al. 2002).
To close the knowledge gap concerning their toxicokinet-
ics and toxicodynamics, the present study aimed to elucidate 
the toxicokinetics of these compounds, including in vitro 
metabolism in pooled human liver S9 fraction (pHLS9) 
incubations in comparison to in vivo metabolites identified 
using the zebrafish larvae model, isozyme mapping, and the 
determination of plasma protein binding (PPB). Toxicody-
namic properties should include characterizing the MOR 
activity in engineered human embryonic kidney (HEK) 
293 T cells as well as maximum-tolerated concentration 
(MTC) studies in zebrafish larvae.
Materials and methods
Chemicals and reagents
4F-Cy-BAP and Fu-BAP were provided as citrate salts for 
research purposes from the EU-project ADEBAR/State 
Bureau of Criminal Investigation Schleswig–Holstein (Kiel, 
Germany). Chemical purity and identity of the compounds 
were verified by mass spectrometry (MS) and nuclear 
magnetic resonance analysis. Stock solutions in methanol 
(1 mg/mL) or DMSO were freshly prepared before each 
experiment. Hydromorphone was purchased as hydromor-
phone HCl from Fagron (Nazareth, Belgium). Fentanyl 
was obtained as a free base from LGC Chemicals (Wesel, 
Germany). Trimipramin-d3, isocitrate, isocitrate dehy-
drogenase, superoxide dismutase, 3′-phosphoadenosine-
5′phosphosulfate (PAPS), S-(5′-adenosyl)-l-methionine 
(SAM), dithiothreitol (DTT), reduced glutathione (GSH), 
magnesium chloride  (MgCl2), potassium dihydrogen 
phosphate  (KH2PO4), dipotassium hydrogen phosphate 
 (K2HPO4), tris hydrochloride, fetal bovine serum (FBS), 
and poly-d-lysin were from Sigma Aldrich (Taufkirchen, 
Germany/Overijse, Belgium) and NADP + from Biomol 
(Hamburg, Germany). Centrifree devices were obtained 
from Merck (Darmstadt, Germany). Dulbecco’s Modified 
Eagle’s Medium (DMEM; GlutaMAX™), Opti-MEM® I 
Reduced Serum Medium, penicillin–streptomycin (5.000 U/
mL) and amphotericin B (250 µg/mL) were purchased from 
Thermo Fisher Scientific (Pittsburg, PA, USA). The Nano-
Glo® Live Cell reagent, which was used for the readout of 
the MOR bioassay, was procured from Promega (Madison, 
WI, USA). Acetonitrile (LC–MS grade), methanol (LC–MS 
grade), ammonium formate (analytical grade), formic acid 
(LC–MS grade), and all other reagents and chemicals (ana-
lytical grade) were from VWR (Darmstadt, Germany). 
Zebrafish embryos were obtained from in-house bred 
adult zebrafish of the AB wild-type line. The baculovirus-
infected insect cell microsomes (Supersomes) containing 
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Fig. 1  Chemical structures of cyclopropanoyl-1-benzyl-4´-fluoro-4-
anilinopiperidine (4F-Cy-BAP), furanoyl-1-benzyl-4-anilinopiperi-
dine (Fu-BAP), and fentanyl. Structural deviations from fentanyl are 
highlighted in red (online version only)
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human cDNA-expressed flavin-containing monooxygenase 
3 (FMO3) (5 mg protein/mL), CYP1A2, CYP2A6, CYP2B6, 
CYP2C8, CYP2C19, CYP2D6, CYP3A4 (1 nmol/mL), 
CYP2C9, CYP2E1, or CYP3A5 (2 nmol/mL), as well as 
pooled human liver microsomes (pHLM, 20 mg microsomal 
protein/mL, 330 pmol total CYP/mg protein), pooled human 
liver S9 fraction (pHLS9; 20 mg microsomal protein/mL), 
UGT reaction mixture solution A (25 mM UDP-glucuronic 
acid), and UGT reaction mixture solution B (250 mM Tris 
HCl, 40 mM MgCl2, and 125 μg/mL alamethicin) were 
supplied by Corning (Amsterdam, The Netherlands). After 
delivery, the enzymes were thawed at 37 °C, aliquoted, snap-
frozen in liquid nitrogen, and stored at − 80 °C until use.
In vitro metabolic stability, identification of in vitro 
metabolites, and plasma protein binding
According to a previous study (Gampfer et al. 2019), pHLS9 
(2 mg microsomal protein/mL) was preincubated for 10 min 
at 37 °C with 25 μg/mL alamethicin (UGT reaction mix-
ture solution B), 90 mM phosphate buffer (pH 7.4), 2.5 mM 
 Mg2+, 2.5 mM isocitrate, 0.6 mM NADP + , 0.8 U/mL 
isocitrate dehydrogenase, 100 U/mL superoxide dismutase. 
Thereafter, 2.5 mM UDP-glucuronic acid (UGT reaction 
mixture solution A), 40 μM PAPS, 1.2 mM SAM, 1 mM 
DTT, 10 mM GSH was added. To ensure a linear metabo-
lism during incubation, the compound concentrations were 
set at 2.5 µM (Baranczewski et al. 2006). The given concen-
trations are concentrations in the final incubation mixtures 
(300 µL final volume). All incubations were done in dupli-
cate. The organic solvent content was kept below 1% (v/v) 
(Chauret et al. 1998).
Reactions were initiated after addition of 4F-Cy-BAP 
or Fu-BAP and continued for 360 min. Meanwhile, 30 µL 
samples were taken after 1, 15, 30, 45, 60, 75, 90, 180, and 
360 min, respectively. Reactions were stopped by adding 
10 µL ice-cold acetonitrile. Afterwards, the samples were 
cooled for 30 min at − 20 °C, centrifuged at 18,407×g for 
2 min, and the supernatants were transferred to autosam-
pler vials, and measured by liquid chromatography high-
resolution tandem MS (LC–HRMS/MS). In order to iden-
tify metabolites formed by  NADP+ independent enzymes, 
incubations without  NADP+ were also performed. Blank 
incubations without substrate and control incubations with-
out enzyme (pHLS9) were prepared to examine whether 
interfering or non-metabolically formed compounds were 
present.
Metabolic stability was determined by declining substrate 
concentration (Wagmann et al. 2019), plotting the natural 
logarithm of the absolute peak area ratios of 4F-Cy-BAP or 
Fu-BAP versus time, respectively. In vitro half-lives were 
calculated by the slope of the respective linear regression. 
A t-test was done to confirm that there was no significant 
difference between the compound concentration at 360 min 
in control incubations and the initial concentrations in the 
pHLS9 incubations at 1 min. GraphPad Prism 5.00 (Graph-
Pad Software, San Diego, USA) was used for statistical cal-
culations with the following defined settings: unpaired; two-
tailed; significance level, 0.05; confidence intervals, 99%.
In vitro half-life (t1/2) and intrinsic clearance  (CLint, 
Eq. 1–3) were determined in accordance to Baranczewski 
et al. (2006). Hepatic clearance  (CLh) was predicted using 
parallel tube model with (Eq. 4) and without (Eq. 5) free 
fraction in plasma (fu) and well-stirred model with (Eq. 6) 
and without (Eq. 7) fu (Obach 1999). Calculations of hepatic 
extraction ratio  (ERh, Eq. 8) were based on Eqs. 5 and 7 
(Mehvar 2018).
t1/2 = in vitro half-life, k = slope of the linear regression fit, 
 CLint = intrinsic clearance, [V]incubation = incubation vol-
ume = 0.3 mL, [P]incubation = amount of S9 protein in the 
incubation = 0.6 mg, [Liver]
[BW]
 = liver weight normalized by body 
weight = 26 g/kg (Davies and Morris 1993), SF = scaling 
factor S9 protein per gram of liver = 121 mg/g (Houston and 
Galetin 2008),  CLh = hepatic clearance, Q = hepatic blood 
flow rate in human = 20 mL/min/kg (Boxenbaum 1980), 
fu = free fraction in plasma, and  ERh = hepatic extraction 
ratio.
PPB studies were done as described earlier (Fung et al. 
2003; Mardal et  al. 2016). Methanolic 4F-Cy-BAP and 
(1)t1∕2, min =
ln 2
k
(2)
ln
[
peak area ratio
]
remaining
= ln
[
peak area ratio
]
initial
− k × t
(3)
CLint, mL∕min∕kg =
ln 2
t1∕2
×
[V]incubation
[P]incubation
×
[Liver]
[BW]
× SF
(4)CLh,mL∕min∕kg = Q ×
(
1 − e
(
−fu× CLint
Q
))
(5)CLh,mL∕min∕kg = Q ×
(
1 − e
(
− CLint
Q
))
(6)CLh,mL∕min∕kg =
Q × fu × CLint
Q + fu × CLint
(7)CLh,mL∕min∕kg =
Q × CLint
Q + CLint
(8)ERh =
CLh
Q
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Fu-BAP solution (final concentration 0.5 µM) were spiked 
into fresh pooled human plasma (500 µL final volume). 
As human blood concentrations of both compounds were 
unknown, the selected plasma concentration was based on 
an average value of two intoxications with the synthetic opi-
oid THF-F (Helander et al. 2017; Krotulski et al. 2018). 
After the incubation was conducted for 30 min at 37 °C, 
a volume of 100 µL (global approach, GA) was taken and 
transferred into a new reaction tube. The remaining sample 
was transferred into an ultrafiltrate device and centrifuged 
at 1600×g for 35 min. Thereafter, a volume of 100 µL of the 
ultrafiltrate (UF) was transferred to a new reaction tube. All 
samples were precipitated by adding a volume of 50 µL of 
ice-cold acetonitrile containing trimipramine-d3 (2.5 µM) as 
internal standard (IS). This was done as there was no deuter-
ated 4F-Cy-BAP or Fu-BAP available and trimipramine-d3 
was shown in be suitable as IS. Afterwards, they were cooled 
for 30 min at − 20 °C, centrifuged for 2 min at 18,407×g, 
and measured by LC-HRMS/MS. Ultrafiltration was done 
in triplicate.
Calculations of PPB were done using the following 
equations:
Isozyme mapping
As described elsewhere (Wagmann et al. 2016) with minor 
modifications, 4F-Cy-BAP and Fu-BAP (2.5 µM) were 
incubated with CYP1A2, CYP2A6, CYP2B6, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, 
CYP3A5 (50 pmol/mL each), FMO3 (0.25 mg protein/mL), 
respectively, or pHLM (1 mg protein/mL) as positive control 
for 30 min at 37 °C. All given concentrations are concentra-
tions in the final incubation mixtures (100 µL final volume). 
In addition, the incubation mixtures contained 90 mM phos-
phate buffer (pH 7.4), 5 mM  Mg2+, 5 mM isocitrate, 0.5 U/
mL isocitrate dehydrogenase, 1.2 mM  NADP+, and 200 U/
mL superoxide dismutase. CYP2A6 and CYP2C9 incuba-
tions were conducted using Tris buffer instead of phosphate 
buffer, according to the manufacturer’s recommendation. 
In a preliminary test, reactions were started by adding the 
enzymes and stopped after 30 min by transferring a vol-
ume of 30 µL into new reactions tubes, which contained 
10 µL ice-cold acetonitrile. Before analysis, the samples 
were centrifuged at 18,407×g for 5 min and the superna-
tants were transferred into autosampler vials. In a second 
(9)fu =
peak area ratio
(
4F−Cy−BAPUF or Fu−BAPUF
ISUF
)
peak area ratio
(
4F−Cy−BAPGA or Fu−BAPGA
ISGA
)
(10)PPB,% =
(
1 − fu
)
× 100
test, only the involved isozymes and pHLM were incubated 
under identical conditions as described above (250 µL final 
volume). Reactions were stopped after 1, 5, 10, 15, 20, 25, 
and 30 min. Blank incubations without substrate and nega-
tive control incubations without enzymes were conducted to 
examine whether interfering or non-metabolically formed 
compounds were present. All incubations were done in 
duplicate.
Maximum‑tolerated concentration (MTC) studies 
in zebrafish larvae
Following the study of Richter et al. (2019a), zebrafish main-
tenance and all experiments with larvae were performed 
according to internal protocols based on standard methods 
(Westerfield 2007). Zebrafish larvae were raised at 28 °C in 
Danieau’s medium consisting of 17 mM NaCl, 2 mM KCl, 
0.12 mM MgSO ⁠4, 1.8 mM Ca(NO ⁠3) ⁠2, 1.5 mM HEPES, 
and 1.2 µM methylene blue. MTC studies were performed 
by placing the collected embryos in 6-well plates with 10 
embryos per well in 2 mL Danieau’s medium. Zebrafish lar-
vae at 4 days post-fertilization (dpf) were exposed to 4F-Cy-
BAP and Fu-BAP dissolved in Danieau’s medium containing 
1% (v/v) DMSO (waterborne exposition). Final compound 
concentrations were 0.01, 0.1, 1, 10, 50, and 100 µM. A 
negative control without drug was prepared, to exclude 
morphological malfunctions caused by DMSO (Xiong et al. 
2017). The well plates remained over 24 h in the incubator 
at 28 °C. All drug exposure tests were done with 20 larvae. 
During exposure, the larvae were monitored using a LEICA 
M205 FA stereo microscope (Leica Mikrosysteme Vertrieb 
GmbH, Wetzlar, Germany).
In vivo identification of metabolites
In compliance with an already described procedure (Richter 
et al. 2019a), 4F-Cy-BAP or Fu-BAP were administered to 
the zebrafish larvae (4 dpf) via medium. One well of a 6-well 
plate contained 10 zebrafish larvae and 2 mL of Danieau’s 
medium spiked with the compound (100 µM 4F-Cy-BAP 
or 80 µM Fu-BAP final concentrations, respectively). Drug 
exposure lasted for 24 h at 28 °C. Afterwards, the larvae 
and surrounding medium were collected separately and 
the medium was frozen at − 20 °C until use. Twenty lar-
vae (from two wells) were transferred into a reaction tube, 
washed twice with 1 mL medium and euthanized by placing 
the tubes in ice water for 15 min. After the wash solution 
was removed, larvae were snap-frozen in liquid nitrogen, 
followed by lyophilization, and stored at − 20 °C until use.
Extraction of the medium was conducted by precipitation 
of 50 µL medium with 50 µL acetonitrile containing 0.1% 
(v/v) formic acid, shaking for 2 min, and cooling for 30 min 
at − 20 °C. Before analysis, the samples were centrifuged at 
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18,407×g for 2 min and the supernatant was transferred to 
an autosampler vial. Twenty larvae (one tube) were extracted 
with 50 µL methanol and shaken for 2 min. After centrifuga-
tion at 18,407×g for 2 min, the supernatant was transferred 
to an autosampler vial. All above described experiments 
were prepared and analyzed in triplicate. Blank zebrafish 
larvae (n = 2) were incubated in the medium without drugs 
and analyzed along with their blank medium to identify 
interfering compounds. Furthermore, a control medium 
sample containing only the drug in Danieau´s medium was 
prepared, respectively, for the detection of compound deg-
radations during incubation.
In vitro µ‑opioid (MOR) receptor activity
To assess the in vitro biological activity of 4F-Cy-BAP and 
Fu-BAP, a live cell-based reporter assay was used that moni-
tors functional complementation of a split nanoluciferase 
(NanoLuc Binary Technology) following agonist-induced 
recruitment of a β-arrestin 2 (βarr2) protein (fused to a small 
part of NanoLuc) to MOR (fused to a large part of Nano-
Luc). Details regarding the development of the stable cell 
line used here have been reported elsewhere (Cannaert et al. 
2017, 2018).
Engineered HEK 293 T cells were routinely maintained 
at 37 °C, 5%  CO2, under humidified atmosphere in DMEM 
supplemented with 10% heat-inactivated FBS, 100 U/mL 
of penicillin, 100 µg/mL of streptomycin and 0.25 µg/mL of 
amphotericin B. Stability of the cell lines was followed by 
flow cytometric analysis. For experiments, cells were plated 
on poly-D-lysine coated 96-well plates at 5 × 104 cells/well 
and incubated overnight. The cells were washed twice with 
Opti-MEM® I Reduced serum medium to remove any 
remaining FBS and 100 µL of Opti-MEM® I was added. 
The Nano-Glo Live Cell reagent, a non-lytic detection rea-
gent containing the cell permeable furimazine substrate, 
was prepared by diluting the Nano-Glo Live Cell substrate 
20-fold using Nano-Glo LCS Dilution buffer, and 25 µL was 
added to each well. Subsequently, the plate was placed in 
the TriStar2 LB 942 multimode microplate reader (Berthold 
Technologies GmbH & Co., Germany). Luminescence was 
monitored during the equilibration period until the signal 
stabilized (15 min). We added 20 µL per well of test com-
pounds, present as 6.75 × stocks (as 20 µL was added to 
135 µL in total) in Opti-MEM® I. The luminescence was 
continuously measured for 120 min. Solvent controls were 
run in all experiments. Curve fitting and statistical analy-
ses were performed using GraphPad Prism. The concentra-
tion–response curves were generated from experiments per-
formed in triplicate, the data points representing the mean 
area under the curve (AUC) ± standard error of mean (SEM). 
All results were normalized to the maximal activity (Emax) of 
hydromorphone (= 100%), used as the reference compound. 
Curve fitting of concentration − effect curves via nonlinear 
regression was employed to determine the potency  (EC50) 
and the efficacy (Emax).
LC–HRMS/MS system
The used Thermo Fisher Scientific (TF, Dreieich, Germany) 
Dionex UltiMate 3000 RS pump was composed of a degas-
ser, a quaternary pump, and an UltiMate autosampler and 
connected to a TF Q-Exactive Plus system equipped with a 
heated electrospray ionization source (HESI)-II. A volume 
of 1 µL was injected for all samples. Gradient elution was 
performed as described earlier (Helfer et al. 2015), using 
a TF Accucore PhenylHexyl column (100 mm × 2.1 mm, 
2.6 μm). The composition of the mobile phases was: 2 mM 
aqueous ammonium formate containing formic acid (0.1%, 
v/v, pH 3, eluent A) and 2 mM ammonium formate solution 
with acetonitrile:methanol (1:1, v/v), water (1%, v/v), and 
formic acid (0.1%, v/v, eluent B). At first, the flow rate was 
set to 500 μL/min for a period of 10 min followed by 800 µL/
min for 10–13.5 min. The gradient was stepped from 0 to 
1 min hold 99% A, 1–10 min to 1% A, 10–11.5 min hold 
1% A, and 11.5–13.5 min hold 99% A. HESI-II source set-
tings were: heater temperature, 320 °C; ion transfer capillary 
temperature, 320 °C; spray voltage, 4.0 kV; ionization mode, 
positive; sheath gas, 60 arbitrary units (AU); auxiliary gas, 
10 AU; sweep gas, 0 AU; and S-lens RF level, 50.0. External 
mass calibrations were done in advance before analysis as 
recommended by the manufacturer. Identification and quan-
tification of parent compounds and metabolites were per-
formed using full scan data and a subsequent data‐depend-
ent  MS2 (dd-MS2) mode with an inclusion list containing 
the exact masses of the respective parent compound and its 
presumed metabolites. Expected phase I metabolites such 
as hydroxy, dihydroxy or N-dealkyl metabolites and phase 
II e.g. sulfates, glucuronides were the inclusion lists. Full 
scan data acquisition was conducted as follows: resolution, 
35,000; microscans, 1; automatic gain control (AGC) target, 
 1e6; maximum injection time (IT), 120 ms; and scan range, 
m/z 50–750. The following settings for the dd-MS2 mode 
were defined: option “pick others”, enabled; dynamic exclu-
sion, disabled; resolution, 17,500; microscans, 1; isolation 
window, 1.0 mass-to-charge ratio (m/z); loop count, 5; AGC 
target,  2e5; maximum IT, 250 ms; high collision dissociation 
cell with stepped normalized collision energy, 17.5, 35.0, 
52.5; exclude isotopes, on; spectrum data type, profile; and 
underfill ratio, 1%. Chemical structure drawings of presumed 
metabolites and exact mass calculations were prepared by 
ChemSketch 2010 12.01 (ACD/Labs, Toronto, Canada). 
Data handling was performed by TF Xcalibur Qual Browser 
software version 2.2. Automated peak integration settings 
were as follows: mass tolerance, 5 ppm; peak detection 
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algorithm, INCOS; baseline window, 40; area noise factor, 
5; and peak noise factor, 10.
Results
In vitro metabolic stability and PPB
Metabolic stability data are summarized in Table S1 in the 
Electronic Supplementary Material (ESM). Non-metabolic 
compound degradation during the pHLS9 incubations 
could be excluded by control incubations as the t-tests did 
not show a significant difference between the parent com-
pound concentration after 360 min in control incubations 
and the initial concentrations after 1 min. Based on decreas-
ing enzyme activities after 2 h of incubation, the cut-off 
value for determination of in vitro half-lives was defined to 
be 90 min (Baranczewski et al. 2006). Since the half-life of 
4F-Cy-BAP was longer than 90 min, no clearance values and 
 ERh were calculated. The half-life of Fu-BAP was 71 min, 
resulting in a  CLint of 15 mL/min/kg. Calculations of fu gave 
values of 0.02 for 4F-Cy-BAP and 0.05 in terms of Fu-BAP 
resulting in a PPB of 98% (4F-Cy-BAP) and 95% (Fu-BAP). 
 CLh predictions of Fu-BAP in consideration of fu resulted in 
0.7 mL/min/kg in both models. In disregard of fu,  CLh values 
were 10.6 mL/min/kg, calculated with the parallel tube and 
8.6 mL/min/kg with the well-stirred model, which gave  ERh 
values of 0.5 and 0.4, respectively.
Identification of in vitro and in vivo metabolites
To avoid redundancies and to ease readability, results of 
in vitro and in vivo metabolite identification will be com-
bined in the following section. Metabolites were identified 
by mining the data recorded in full-scan mode for their on 
beforehand calculated exact precursor ions (PIs). Subse-
quently, the spectra of the tentative metabolites obtained 
from the dd-MS2 mode were compared to that of the respec-
tive parent compound. All metabolites are listed in Table S2 
in the ESM along with their metabolite ID, PI recorded in 
 MS1, characteristic fragment ions (FIs) in  MS2, relative 
intensities, calculated exact masses, elemental composition, 
mass deviation errors of the most abundant FIs, and reten-
tion time (RT). The in vitro and in vivo metabolic pathways 
of 4F-Cy-BAP and Fu-BAP are depicted in Fig. 2 and Fig. 3, 
respectively. In total, 7 phase I and 1 phase II metabolites 
of 4F-Cy-BAP and 15 phase I and 4 phase II metabolites in 
case of Fu-BAP were tentatively identified. The  MS2 spectra 
of 4F-Cy-BAP or Fu-BAP and their three most abundant 
in vitro and in vivo metabolites are given in Figs. 4 and 
5, respectively. In addition, the  MS2 spectra of the lower 
abundant metabolites are represented in Fig. S1 (4F-Cy-
BAP) and Fig. S2 (Fu-BAP) in the ESM.
In the following section, only exact masses will be used 
for the characterization of parent compounds and their 
respective metabolites. High abundant but less character-
istic FIs of 4F-Cy-BAP (PI at m/z 353.2023) as well as 
Fu-BAP (PI at m/z 361.1910) were FIs at m/z 174.1277 
and at m/z 91.0542. The former fragment originated from 
the benzyl piperidine part of the compounds and the latter 
of the phenyl coupled to the methyl spacer after piperidine 
cleavage. A distinctive fragment of 4F-Cy-BAP was the 
FI at m/z 246.1288, which was generated after the separa-
tion of the piperidine nitrogen plus benzyl part. Another 
prominent FI at m/z 69.0334 contained the cyclopropyl 
and carbonyl moiety formed after amide cleavage. Equally, 
distinguishing FIs of Fu-BAP were the less abundant FI 
at m/z 254.1175 and the FI at m/z 95.0127, which differed 
from the  MS2 fragments of 4F-Cy-BAP through substitu-
tion of the cyclopropyl with the furanyl group.
One of the most abundant metabolites of 4F-Cy-BAP was 
M1 (PI at m/z 263.1554), which originated from N-dealkyla-
tion at the piperidine nitrogen. A characteristic FI was FI at 
m/z 180.0819, which consisted of the fluorophenyl linked to 
the cyclopropyl moiety. M2 (PI at m/z 285.1761), showed 
a similar fragmentation pattern as the parent compound, 
except for the missing FI at m/z 69.0334, which represented 
the cyclopropyl and carbonyl moiety. N-oxidation of the 
piperidine nitrogen led to the formation of M7 (PI at m/z 
369.1972). The characteristic FI at m/z 98.0600 correlated 
with FI at m/z 84.0807 varying in one oxygen and two miss-
ing hydrogen atoms.
The Fu-BAP metabolite M9 (PI at m/z 267.1855) emerged 
from N-deacylation at the amide. Its  MS2 spectrum was sim-
ilar to that of the parent compound, except for the FI at m/z 
95.0127, which originated from the furanyl part. M10 (PI at 
m/z 271.1441) was formed by N-dealkylation at the piperi-
dine nitrogen and specified by FI at m/z 188.0706, which 
was generated after separation of the piperidine. M15 (PI 
at m/z 377.1859) was one of two hydroxy isomers, with the 
hydroxy group located at the phenyl part, which was part 
of the benzyl moiety. The FI at m/z 107.0491 corresponded 
to the FI at m/z 91.0548, which was altered by one oxygen 
atom. Both hydroxy isomers (M15, M16) were distinguish-
able from each other by different RT and intensities.
The N-deacyl hydroxy metabolite of 4F-Cy-BAP, M3 (PI 
at m/z 301.1710) was formed by N-deacylation at the amide 
and followed by hydroxylation at the phenyl, which was rep-
resented by the prominent FI at m/z 107.0491. N-Deacyla-
tion followed by N-oxidation of the linker nitrogen between 
piperidine and fluorophenyl led to the formation of M4 (PI 
at m/z 301.1710). A characteristic FI of M4 was FI at m/z 
193.1135, which was matched with the fluorophenyl part 
linked to the piperidine ring with one double bond indicating 
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loss of water. The two hydroxy isomers M5 and M6 (PI at 
m/z 369.1972) were formed by hydroxylation at the phe-
nyl part. As already described for the Fu-BAP metabolite 
M15, M5 and M6 were characterized by the same FI at m/z 
107.0491. A differentiation between both isomers was pos-
sible by different RT. The phase II metabolite M8 (PI at m/z 
545.2293) was formed by glucuronidation of M5 or M6, 
which was also identified by the FI at m/z 107.0491.
M11 and M12 (PI at m/z 283.1804) were two Fu-BAP 
metabolites formed by N-deacylation plus hydroxylation. 
M12 was the equivalent N-deacyl metabolite of M15 or 
M16, which was characterized by FI at m/z 107.0491. The 
hydroxylation of M11 (PI at m/z 283.1804) occurred at the 
phenyl, which was designated by FI at m/z 192.1258 origi-
nating from elimination of the benzyl part. M13 (PI at m/z 
305.1495) was formed by N-dealkylation and dihydrodiol 
formation by epoxidation of one double bond at the fura-
nyl, followed by a non-enzymatic hydrolysis. Identification 
of M13 followed FI at m/z 166.0862, which contained the 
phenyl linked to a remaining part of the furanyl. M14 (PI 
at m/z 363.1373) stemmed from M11 through sulfation of 
the hydroxy group and their  MS2 spectra were in accord-
ance to each other. The second hydroxy isomer M16 (PI at 
m/z 377.1859) showed a similar fragmentation pattern as 
M15. M17 (PI at m/z 377.1859) originated from N-oxidation 
of the piperidine nitrogen, which was also specified with 
FI at m/z 98.0600, as already described for M7 of 4F-Cy-
BAP. The 2,5-dihydroxypent-2-enal metabolite M18 (PI at 
m/z 381.2172) occurred through oxidative opening of the 
furan ring, which was identified by FI at m/z 363.2067 and 
FI at m/z 174.1277. The former fragment indicated a loss 
of water and due to the presence of the latter, which was 
unchanged compared to parent compound, the water loss 
was located at the opened furan ring. Aromatic dihydroxy-
lation led to the formation of M19 (PI at m/z 393.1808), 
with the hydroxy groups located at the phenyl being part of 
the benzyl. The specific FI at m/z 123.0440 represented the 
dihydroxylated benzyl moiety, which differed in two oxygen 
atoms to the FI at m/z 91.0548. The dihydrodiol metabo-
lite M20 (PI at m/z 395.1965) was characterized due to the 
Fig. 2  In vitro and in vivo meta-
bolic pathways of 4F-Cy-BAP. 
Metabolites in brackets are 
considered to be artifacts
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absence of FI at m/z 95.0127, which was assigned to the 
furanyl part. M21 (PI at m/z 407.1965) occurred through 
methylation of one hydroxy group at the catechol structure 
of M19. The pronounced FI at m/z 137.0597 corresponded 
to FI at m/z 107.0491, which was altered by one additional 
methoxy group. The dihydroxy-5-oxopent-3-enoic acid 
metabolite M22 (PI at m/z 411.1914) originated from oxi-
dative furan ring opening, oxidation of the terminal hydroxy 
group to carboxylic acid, and an additional hydroxylation at 
the opened side chain as described for the saturated furan 
ring of a fentanyl analogue (Kanamori et al. 2019). The low 
abundant FI at m/z 367.2016, which indicated an elimination 
of carbon dioxide, was used for its characterization. Based 
on its  MS2 spectrum, the hydroxy group could be attached 
to position 2 or 3 at the chain, but the exact position was 
not locatable. M23, M24, and M25 (PI at m/z 411.1914) 
were three dihydrodiol-hydroxy isomers. In case of M23 
and M25 the hydroxy group was determined at the phenyl, 
which belonged to the benzyl moiety, by means of FI at m/z 
107.0491. Although the hydroxy group of M24 was located 
at the furanyl part, due to the presence of FI at m/z 267.1855, 
which resulted from the cleavage of the furanyl moiety, the 
precise structure of the furanyl residue was not determinable. 
Therefore, the most likely ring-closed structure is given for 
M24. The phase II metabolite M26 (PI at m/z 473.1376) was 
formed by sulfation of one hydroxy group of M21. It was 
specified by the FI at m/z 203.0008, which correlated to the 
FI at m/z 123.0440, differing in one sulfate group. M27 (PI 
at m/z 553.2180) was the corresponding phase II metabolite 
of M15 or M16, which was formed by glucuronidation of 
the hydroxy group. The prominent FI at m/z 107.0491 was 
used for identification. In the negative control incubations of 
all in vitro models and in the zebrafish larvae control media, 
the N-deacyl-metabolites M2 and M9 were also present with 
similar peak intensities as in the corresponding incubations 
with enzymes. However, in incubations without  NADP+ 
solely the peak intensity of M9 increased. Blank incubations 
confirmed the absence of interfering compounds.
Isozyme mapping
Blank incubations confirmed the absence of interfering com-
pounds. The involvement of single isozymes compared to 
pHLS9 and pHLM incubations of both compounds is listed 
in Table S3 in the ESM.
N-Dealkyl 4F-Cy-BAP (M1) was present in incuba-
tions of CYP1A2, CYP2C19, CYP3A4, and CYP3A5. 
Furthermore, CYP2C19 catalyzed the formation of the 
two hydroxy isomers (M5, M6). The former (M5) was also 
formed by CYP2D6. CYP3A4 and CYP3A5 contributed 
to the emergence of the N-oxide (M7). Equally, several 
isozymes catalyzed the formation of the N-dealkyl Fu-BAP 
(M10), namely CYP1A2, CYP2C8, CYP2C19, CYP2D6, 
and CYP3A4. Apart from that, CYP2C8 was only involved 
in the formation of the N-oxide (M17). CYP2C19 contrib-
uted to numerous different steps, amongst them the forma-
tion of the two hydroxy isomers (M15, M16), the N-oxide 
(M17), and the furan ring opened 2,5-dihydroxypent-2-enal 
metabolite (M18). CYP2D6 was involved in the formation 
of the dihydrodiol metabolite (M20), the furan ring opened 
dihydroxy-5-oxopent-3-enoic acid metabolite (M22), as well 
as the dihydrodiol-hydroxy metabolite (M24). CYP3A4 was 
another considerable isozyme, catalyzing, besides M10 the 
formation of the hydroxy isomer (M15), the N-oxide (M17), 
and the dihydrodiol-hydroxy metabolite (M24).
MTC studies in zebrafish larvae
Survival rates of the 4 dpf larvae exposed for 24  h to 
both compounds at concentrations of 0.01, 0.1, 1, 10, 50, 
and 100 µM were 100%. However, after treatment with 
100 µM Fu-BAP, 80% of the larvae showed malformations 
and changes in behavior. An influence of DMSO could 
be excluded by the negative control incubation. Figure 6 
shows a larva in control Danieau’s medium (a) or treated 
with 100 µM Fu-BAP (b), both containing 1% (v/v) DMSO. 
Visible morphological changes manifested in a spinal curva-
ture (1), abnormal pericardial edema (2), and a dark brown 
colored yolk sac (3), which has already been described e.g. 
Fig. 6  Microscopic image of 
two zebrafish larvae (a) in 
control medium (Danieau’s 
medium) plus 1% DMSO 
and (b) in Danieau´s medium 
containing 100 µM Fu-BAP 
plus 1% DMSO. Morphological 
malfunctions were a spinal cur-
vature (1), abnormal pericardial 
edema (2), and a dark brown 
colored yolk sac (3)
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for environmental toxins (Seok et al. 2008). Furthermore, 
various larvae were observed, which showed random body 
vibrations, a fast heartbeat, and slow movements after touch-
ing. To prevent toxic effects in subsequent in vivo experi-
ments, the Fu-BAP concentration was reduced to 80 µM 
for the metabolism study. However, still 20% of the larvae 
exhibited morphological/behavioral changes after exposure 
to 80 µM Fu-BAP in the metabolism study.
Determination of the in vitro activity at MOR
Analysis of the in vitro MOR activation potential of 4F-Cy-
BAP and Fu-BAP showed an Emax of 5.98% and 0.98%, 
respectively, compared to the reference compound hydro-
morphone (Emax of 100%) and fentanyl (Emax of 180%), as 
presented in Fig. 7 and also summarized in Table S4 in the 
ESM along with their  EC50 values.
Discussion
In vitro metabolic stability, predicted in vivo 
clearance, and PPB
Metabolic stability was characterized by t1/2,  CLint,  CLh, and 
 ERh.  CLint differs from  CLh in the independence of physi-
ological factors, such as hepatic blood flow and drug binding 
(Baranczewski et al. 2006). In vitro t1/2 was determined by 
decreasing 4F-Cy-BAP or Fu-BAP amounts during incuba-
tion with pHLS9 from 1 till 90 min. As several incubations 
were prepared at once, the first samples had to be taken at 
t = 1 min.  CLint of Fu-BAP was rated to be low in accordance 
to McNaney et al. (2008). No half-life and clearance values 
of 4F-Cy-BAP could be determined as it demonstrated only 
weak metabolic degradation.
CLh was predicted by parallel tube and well-stirred 
model. The parallel tube model describes the liver as a set 
of tubes representing a sinusoid, with the drug concentra-
tion exponentially decreasing in the direction of the hepatic 
vein (Choi et al. 2019). However, the liver is considered as 
a single, well-mixed compartment with a fixed drug concen-
tration in the well-stirred model (Segers et al. 2019).  CLh 
values of Fu-BAP were identical in both models by consider-
ing fu.  CLh predictions without fu led to much higher values 
in both models.
ERh estimations provide insight into the oral bioavail-
ability of drugs under consideration of  Qh (Benet and Zia-
Amirhosseini 1995). The calculated  ERh was based on  CLh 
values without fu and it could be classified as intermediate 
in both models in accordance to Rogge and Taft (2009). 
As expected, no significant differences between both mod-
els were found, because this is rather the case for high  ERh 
drugs (Mehvar 2018).
Based on the free drug theory (Bohnert and Gan 2013), 
toxicokinetic effects of drugs, e.g. distribution or excretion, 
depends on their fu, which is strongly linked with their PPB. 
As both compounds showed a high PPB of more than 90%, 
a simultaneous intake with other drugs of abuse with simi-
lar high PPB such as cannabinoids (Mardal et al. 2016) or 
NBOMes (Richter et al. 2019b) could lead to an accumula-
tion and adverse effects by displacement from the binding 
site. Moreover, a PPB higher than 70% is expected to have 
an impact on e.g. the clearance (Lindup and Orme 1981). 
However, another study indicated that in particular, clear-
ance predictions of basic compounds based on in vitro meas-
urement are more consistent with in vivo data regardless of 
any drug binding (Obach 1999). In addition, other influenc-
ing factors must be considered, e.g. active transport into the 
hepatocytes or elimination route (Smith et al. 2010).
Comparison of in vitro and in vivo metabolites
Although in vitro metabolism studies may have some advan-
tages, e.g. cost-effectivity or feasibility, there is often a dis-
crepancy between the metabolites identified in vitro to those 
in human (Richter et al. 2019a). As no human samples after 
intake of 4F-Cy-BAP or Fu-BAP were available, an addi-
tional in vivo assay should confirm possible main targets 
Fig. 7  Concentration-dependent 
interaction of µ-opioid (MOR) 
receptor with β-arrestin 2 
(βarr2) protein upon stimulation 
with hydromorphone (HM), fen-
tanyl, 4F-Cy-BAP and Fu-BAP 
in (a) full concentration curves 
or (b) zoom on lower part of 
the graph. Data are given as 
mean receptor activation ± SEM 
(n = 3), normalized to the Emax 
(maximal activity) of HM 
(= 100%)
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for toxicological screenings. Comparison of the identified 
in vitro and in vivo metabolites in all investigated models of 
4F-Cy-BAP and Fu-BAP are summarized in Table 1. The 
largest number of 4F-Cy-BAP and Fu-BAP metabolites (7 
and 16, respectively) were identified in the zebrafish larvae 
extracts. These metabolites included all metabolites previ-
ously detected in the pHLS9 and pHLM incubations as well 
as in the zebrafish larvae media plus two novel 4F-Cy-BAP 
and eight Fu-BAP metabolites. However, all phase II metab-
olites were exclusively identified in zebrafish larvae extracts. 
This finding is due to the missing cofactors for the phase II 
enzymes in the pHLM incubations. In the case of pHLS9 
incubations, the lower substrate concentration and shorter 
incubation time compared to the zebrafish larvae experi-
ments are expected to be the main causes.
As shown in Fig. 8, the in vitro formation of the N-dea-
cyl-metabolite of 4F-Cy-BAP (M2) had its peak already 
within the first minute of incubation and declined afterwards 
most likely due to further biotransformation to M3. How-
ever, its formation was also observed in stock solutions after 
long-term storage and negative control incubations and thus, 
it may be also of artificial nature. Its subsequent metabo-
lites (M3, M4) were also marked to be possible artifacts 
e.g. in Table 1. Similar findings were observed for Fu-BAP. 
Table 1  List of 4F-Cy-BAP and Fu-BAP metabolites, respectively detected in zebrafish larvae incubations, pHLS9 or pHLM incubations, which 
were rated from + to +  +  + according to their absolute peak areas
Metabolite IDs correspond to Table S2 in the ESM
N.D. not detected
*Considered to be artifacts, — formation with the given incubation conditions not possible
Parent compound
Metabolite ID
Metabolic reaction In vivo In vitro
Zebrafish larvae
Larvae extract 24 h Medium 
24 h
pHLS9 6 h pHLM 0.5 h
4F-Cy-BAP
 M1 N-Dealkylation  +  +  +  +  +  +  +  + 
 M2* N-Deacylation  +  +  +  +  +  +  +  + 
 M3* N-Deacylation + hydroxylation  +  +  +  +  + 
 M4* N-Deacylation + N-oxidation  +  +  + N.D N.D N.D
 M5 Hydroxylation isomer 1  +  +  + N.D N.D
 M6 Hydroxylation isomer 2 N.D N.D N.D N.D
 M7 N-Oxidation  +  +  + N.D  +  +  + 
 M8 Hydroxylation + glucuronidation  + N.D N.D −
Fu-BAP
 M9 N-Deacylation  +  +  +  +  +  +  +  +  + 
 M10 N-Dealkylation  +  +  +  +  +  +  +  + 
 M11 N-Deacylation + hydroxylation isomer 1  + N.D  +  +  +  + 
 M12 N-Deacylation + hydroxylation isomer 2  +  + N.D  +  + 
 M13 N-Dealkylation + epoxidation + hydrolyze (dihydrodiol)  + N.D N.D N.D
 M14 N-Deacylation + hydroxylation + sulfation  +  + N.D N.D −
 M15 Hydroxylation isomer 1  +  +  +  +  +  + 
 M16 Hydroxylation isomer 2 N.D N.D N.D N.D
 M17 N-Oxidation  +  +  + N.D  +  +  + 
 M18 Oxidation (furan ring open)  +  +  +  + N.D  + 
 M19* Dihydroxylation  + N.D N.D N.D
 M20 Epoxidation + hydrolyze (dihydrodiol)  +  + N.D  +  +  + 
 M21 Dihydroxylation + methylation  +  + N.D N.D −
 M22 Oxidation (furan ring open, carboxylic acid) + hydroxylation N.D N.D N.D N.D
 M23 Epoxidation + hydrolyze + hydroxylation isomer 1  + N.D N.D N.D
 M24 Epoxidation + hydrolyze + hydroxylation isomer 2 N.D N.D N.D N.D
 M25 Epoxidation + hydrolyze + hydroxylation isomer 3  + N.D N.D N.D
 M26 Dihydroxylation + sulfation  + N.D N.D −
 M27 Hydroxylation + glucuronidation  +  + N.D N.D −
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However, based on an increasing peak intensity of M9 in 
absence of  NADP+, M9 and all metabolites derived thereof 
were presented as metabolites. Some metabolites (M6, 
M16, M22, M24) were solely detected in single isozyme 
incubations and therefore considered as minor metabolites. 
Moreover, it can be assumed that the origin of the Fu-BAP 
metabolite M19 was artificial because the retention time cor-
related with that of M26. Nevertheless, M19 was obliged to 
be a precursor of the phase II metabolites M21 and M26, but 
most probably with another RT. Suitable analytical targets 
for toxicological urine screenings should be the N-dealkyl 
metabolites (M1, M10) and the N-deacyl metabolites (M2, 
M9) of both compounds, and additionally 4F-Cy-BAP 
N-oxide (M7), as well as hydroxy Fu-BAP (M15).
Involvement of CYP2D6, CYP3A4, and other 
isozymes in phase I steps
Isozyme mapping is essential for the prediction of possible 
interactions, e.g. drug-drug interactions, or interindividual 
variations by different expressions of isozymes. Figure 8 
summarizes the change in the amount of each parent com-
pound in the incubations of pHLS9, pHLM, and in incuba-
tions of all involved isozymes. The formation rates of the 
three most abundant metabolites and the change in amount 
of each parent compound in pHLS9, pHLM, CYP2C19 
or CYP2D6, and CYP3A4 incubations are also given in 
Fig. 8. In particular, 4F-Cy-BAP was mainly metabolized 
by CYP3A4, which may result in increased drug levels and 
intoxications after co-consumption of CYP3A4 inhibitors, 
e.g. tryptamines (Dinger et al. 2016). Due to the additional 
involvement of CYP2D6 in the Fu-BAP metabolism, inhibi-
tion of CYP3A4 is expected to be less substantial if the user 
is not a CYP2D6 poor metabolizer.
In vitro MOR receptor activity
The receptor activation was evaluated via the interaction 
between βarr2, a cytosolic protein, and the G-protein cou-
pled MOR. Both βarr2 and MOR are fused to an inactive 
part of nanoluciferase. When MOR is activated by a ligand, 
βarr2 is recruited to the receptor, allowing interaction of 
the complementary nanoluciferase subunits, yielding a func-
tional enzyme that generates a bioluminescent signal in the 
presence of the substrate furimazine (Cannaert et al. 2019). 
In vitro MOR activity analysis of 4F-Cy-BAP and Fu-BAP 
revealed that these compounds were only able to activate 
MOR to a limited extent. Also the  EC50 values of both com-
pounds were strongly reduced compared to hydromorphone 
and fentanyl.
These findings are not surprising as in  vivo stud-
ies in mice and rat showed that the replacement of the 
N-phenethyl group with a N-benzyl group resulted in a 
strong reduction in anti-nociceptive activity (Casy et al. 
1969; Casy and Huckstep 1988). Moreover, the N-benzyl 
analog of fentanyl (benzylfentanyl) was originally listed 
in the US as a Scheduled I controlled substance, but was 
removed from the list as the Drug Enforcement Adminis-
tration (DEA) indicated that this compound was inactive at 
MOR (DEA and DoJ 2010), in line with our unpublished 
findings.
Conclusion
The current study focused on the toxicokinetic and toxicody-
namic properties of the fentanyl homologs 4F-Cy-BAP and 
Fu-BAP. As 4F-Cy-BAP was metabolically much more stable 
with an in vitro  t1/2 greater than 90 min, no clearances and 
 ERh were calculated. Predicted  CLint and  ERh values of Fu-
BAP were classified as low and intermediate, respectively. 
The higher in vitro metabolic stability of 4F-Cy-BAP was 
confirmed by a smaller number of metabolites formed in vitro 
and in vivo in comparison to Fu-BAP. Overall, seven phase 
I and one phase II metabolites of 4F-Cy-BAP and 15 phase 
I and four phase II metabolites for Fu-BAP were identified, 
with the majority detected in zebrafish larvae. In particular, 
N-dealkylation, hydroxylation, N-oxidation, and N-deacyla-
tion were the main metabolic reactions. Therefore, these 
metabolites should be considered as useful targets for toxico-
logical urine screenings. CYP3A4 and, in the case of Fu-BAP, 
additionally CYP2D6, were the two isozymes mainly involved 
in their in vitro phase I metabolism. Based on these findings, 
drug-drug interactions leading to CYP3A4 inhibition may 
cause an accumulation especially of 4F-Cy-BAP. CYP2D6 
poor metabolizers could be equally affected by drug-drug 
interactions after intake of Fu-BAP. A simultaneous intake 
together with high protein bound drugs could lead to adverse 
reactions by displacement from the binding site. Treatment 
of larvae with Fu-BAP revealed malformations and changes 
in behavior. Only a weak activity at MOR (Emax values of 
5.98% and 0.98% compared to HM, respectively) could be 
observed in vitro but strong agonism or antagonism at other 
Fig. 8  Changes of the amount of parent compounds in pHLS9, 
pHLM, and isozyme incubations (a) 4F-Cy-BAP and (f) Fu-BAP are 
presented as changes in the logarithm of the absolute peak areas as a 
function of time (min). The formation rates of the three most abun-
dant metabolites are depicted in comparison to the changes of the 
logarithmic absolute peak areas of parent compounds (4F-Cy-BAP, 
b–e) and (Fu-BAP, g–j) in pHLS9 b, g, pHLM c, h, CYP2C19 d, 
CYP2D6 i or CYP3A4 e, j. The metabolite marked with an asterisk is 
considered to be an artifact. If data points are missing, no signal was 
detected
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receptors such as the sigma1, sigma2 or acetylcholine M2 and 
M3 receptors cannot be excluded and should be investigated.
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